Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
8
×
clinical trials
8
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
8
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
biotech
boston top stories
bristol-myers squibb
fda
abbvie
alzheimer's disease
cancer
cancer immunotherapy
deals
eli lilly
gene therapy
glaxosmithkline
novartis
What
bio
8
×
roundup
drug
news
week
alzheimer’s
biogen
biogen’s
biotech
days
ipo
nash
acquisitions
aducanumab
advanced
alliance
america
amyloid
angst
announced
annual
approval
arrival
assessed
attention
august
award
bagged
billions
biopharmaceutical
brammer
bristol
busy
buy
calls
cancer
ceo
changing
collabs
color
Language
unset
Current search:
biogen
×
bio
×
" seattle top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More